News for INmune Bio, Inc. (INMB)

On February 26, 2025, Dauntless Investment Group, LLC (Trades, Portfolio) made a strategic move by acquiring 108,224 shares of AEON Biopharma Inc. The transacti

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio, Inc.

**media[538627]**

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 1

**media[536560]**

The Company reports results of a double-blinded, randomized, placebo-controlled study, known as ”œMissionEB,” investigating CORDStrom for treatment of RDEB i

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio Inc (NASDAQ:INMB) stands against the...

**media[526227]**

Significant Transaction by Praetorian PR LLC (Trades, Portfolio) On January 15, 2025, Praetorian PR LLC (Trades, Portfolio) executed a noteworthy transaction in

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and...

Financial writer notes INmune Bio, Inc.'s 2024 decline but sees potential in Alzheimer's research, advising cautious Buy sentiment. Click for this INMD update.

OmniScience Inc. and INmune Bio Inc. (INMB), a clinical-stage biotechnology company, announced a partnership on Tuesday to enhance the operations of INmune Bio's global Phase 2 Alzheimer's disease trial, dubbed AD02, using OmniScience's innovative Vivo platform.

Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec.

**media[465085]**

Net Loss: Approximately $12.1 million for Q3 2024, compared to $8.6 million in Q3 2023.Research and Development Expenses: Approximately $10.1 million for Q3 20

INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ETCompany ParticipantsDavid Moss - CFORaymond Tesi - CEO &...

**media[453192]**

INmune Bio Inc (INMB) is set to release its Q3 2024 earnings on Oct 31, 2024. The consensus estimate for Q3 2024 revenue is $0 million, and the earnings are exp

Read Big Cypress Acquisition (OTCMKTS:BCYP) and INmune Bio (NASDAQ:INMB) Critical Analysis at ETF Daily News